Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Redasemtide versus placebo after coronary artery bypass surgery in ischemic cardiomyopathy
jRCT2051240065Phase 2Active, not recruiting
- Sponsor
- Shionogi Pharma
- Start
- Oct 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in ischaemic cardiomyopathy (ICM) comparing Redasemtide with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Oct 2024; status: active, not recruiting.
02
Drugs
redasemtide
03
Conditions
ischaemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on jRCT2051240065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240065.